Deus ex makena?

Obstetrics and Gynecology

Volumn 117, Issue 6, 2011, Pages 1263-1265

  Silver, Robert M ^a   Cunningham, F Gary ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYPROGESTERONE; PROGESTERONE;

DRUG EFFICACY; ECHOGRAPHY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GESTATION PERIOD; HUMAN; PERINATAL MORBIDITY; PREMATURE LABOR; PRIORITY JOURNAL; UTERINE CERVIX;

ADMINISTRATION, INTRAVAGINAL; FEMALE; HUMANS; HYDROXYPROGESTERONES; PREGNANCY; PREMATURE BIRTH; PROGESTERONE; PROGESTINS;

EID: 79958133185     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31821c6fb1     Document Type: Editorial

References (11)

1. Cohen AW, Copel JA, Macones GA, Menard MK, Riley L, Saade GR. Unjustified increase in cost of care resulting from U.S. Food and Drug Administration approval of Makena (17-hydroxyprogesterone caproate). Obstet Gynecol 2011; 117:1408-12.
2. Armstrong J. Unintended consequences: the cost of preventing preterm births after FDA approval of a branded version of 17OHP. N Engl J Med 2011;Mar 16 [Epub ahead of print].
3. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate [published erratum appears in N Engl J Med 2003;349:1299]. N Engl J Med 2003;348:2379-85.
4. Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007;357: 454-61. (Pubitemid 47204874)
5. Caritis SN, Rouse DJ, Peaceman AM, Sciscione A, Momirova V, Spong CY. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Obstet Gynecol 2009;113:285-92.
6. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188: 419-24. (Pubitemid 36249980)
7. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH, Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007;357:462-9. (Pubitemid 47204875)
8. O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007;30:687-96. (Pubitemid 47612689)
9. Dodd JM, Crowther CA. The role of progesterone in prevention of preterm birth. Int J Womens Health 2010;1: 73-84.
10. Rode L, Langhoff-Roos J, Andersson C, Dinesen J, Hammerum MS, Mohapeloa H, et al. Systematic review of progesterone for the prevention of preterm birth in singleton pregnancies. Acta Obstet Gynecol Scand 2009;88: 1180-9.
11. Use of progesterone to reduce preterm birth. Committee Opinion No. 419. American College of Obstetricians and Gynecologists. Obstet Gynecol 2008;112:963-5.